Acquired resistance to chemotherapy is the major barrier in the treatment of many cancers. Thus, the development of new therapeutic approaches to overcome this limitation and improve patients' outcomes is urgently needed. The addition of new compounds that negatively regulate genes involved in chemoresistance processes may help to overcome this obstacle. Here, we demonstrate that the natural carotenoid β-cryptoxanthin negatively regulates ΔNp73, an oncogenic variant of TP73 gene involved in drug resistance processes. Importantly, we propose a novel therapeutic strategy for the treatment of colon cancer based on the combination of β-cryptoxanthin with a conventional chemotherapeutic drug, oxaliplatin. The combined regimen produced more benefit than either individual treatment, without increasing side effects. In addition, the concentration-limiting toxicity of oxaliplatin could be reduced in the presence of the carotenoid.
SIGNIFICANCE STATEMENT
Acquired resistance to chemotherapy is the major barrier in the treatment of many cancers. Thus, the development of new therapeutic approaches to overcome this limitation and improve patients' outcomes is urgently needed. The addition of new compounds that negatively regulate genes involved in chemoresistance processes may help to overcome this obstacle. Here, we demonstrate that the natural carotenoid β-cryptoxanthin negatively regulates ΔNp73, an oncogenic variant of TP73 gene involved in drug resistance processes. Importantly, we propose a novel therapeutic strategy for the treatment of colon cancer based on the combination of β-cryptoxanthin with a conventional chemotherapeutic drug, oxaliplatin. The combined regimen produced more benefit than either individual treatment, without increasing side effects. In addition, the concentration-limiting toxicity of oxaliplatin could be reduced in the presence of the carotenoid.
INTRODUCTION
Diet certainly plays an important role in preventing cancer, but the underlying mechanism is still not clear. Epidemiological evidence links consumption of carotenoids with decreased risk of various types of cancer (1) (2) (3) (4) . β-cryptoxanthin is one of the six major carotenoids routinely measured in human serum. It is contained primarily in citrus fruits (5, 6) , but also found in corn, peas and some yellow animal products.
Numerous prospective studies show that serum levels of β-cryptoxanthin are inversely associated with the risk of a variety of cancers in several tissues (3, (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) .
However, controversial results have been published, such as those describing no association between β-cryptoxanthin and risk of colon (20) , breast (21) , ovarian (22) and prostate cancer (23) and non-Hodgkin lymphoma (24) .
Additionally, several studies have demonstrated the protective effect of β-cryptoxanthin in carcinogenic-induced tumors of various tissues in animal models (4, (25) (26) (27) (28) . In contrast, few studies examine its possible therapeutic potential. Thus, in vitro, β-cryptoxanthin suppresses the growth of immortalized human bronchial epithelial cells and non-small-cell lung cancer cells (29) , stomach tumor cells (30) and melanoma (31) . The mechanism by which β-cryptoxanthin exerts these effects remains largely unexplored (1) . These findings nevertheless indicate that β-cryptoxanthin could be used as an antitumor compound.
Oxaliplatin, a third-generation platinum-based chemotherapy drug (32) , has a major impact on the management and outcome of colorectal cancer patients (33) Author Manuscript Published OnlineFirst on May 28, 2015; DOI: 10.1158/1078-0432.CCR- colorectal cancer is still acquired resistance. The addition of new compounds to these treatments may overcome this obstacle and improve upon the outcomes currently achieved. In addition, new strategies that can diminish the neurotoxic effects of such treatments would be of interest (33) . Our group has demonstrated the involvement of ∆NP73, an oncogenic variant of the TP73 gene, in proliferative and oxaliplatin chemoresistance processes. Its overexpression is associated with lower survival rates in colon cancer patients (32) , which points to a putative role as a therapeutic target.
In the present study β-cryptoxanthin in combination with oxaliplatin significantly enhanced apoptosis of colon cancer cells in vitro and in vivo. The combined treatment led to similar growth inhibition to those consisting of double individual oxaliplatin doses, which could eventually reduce the effective dose of oxaliplatin and therefore, the associated side effects. Accordingly, the Comet Assay showed a reduction of the genomic damage in healthy cells from those mice treated with the combined regimen. Finally, we identified the down-regulation of ∆NP73 variant as the mechanism underlying these effects. A human intervention study with a β-cryptoxanthin-enriched juice supports the in vivo regulation of P73 variants by this carotenoid.
MATERIALS AND METHODS

Cell culture
Human colon cancer cell lines HCT116 and SW1417 were obtained from the Author Manuscript Published OnlineFirst on May 28, 2015; DOI: 10.1158/1078-0432.CCR- Aliquots from the stock solution were added to the cell culture medium at the desired working concentration. The final THF concentration in cell culture medium was 0.2% v/v. Control culture received only THF. Cells were plated on 6-well plates (2x10 5 cells/well) and grown overnight to allow for cell attachment. Cells were then treated with medium supplemented with β-cryptoxanthin or vehicle (0.2% THF v/v) for several periods of time. Cell culture medium was changed every 24 hours. All procedures were performed in the dark.
Intervention study and lymphocyte extraction
Twenty anonymous healthy volunteers were selected by non-probabilistic sampling. All participants were required to have biochemical and haematological profiles and serum levels of vitamin A, E and carotenoids within accepted reference ranges (5) . The use of vitamin and/or herbal supplements, dieting, pregnancy, chronic medication or intercurrent disease or infection that could alter the bioavailability or status of the compounds of interest was used as exclusion criteria.
A juice containing 0.75 mg of β-cryptoxanthin was given to the healthy donors daily for one month. Although no side effects were expected from the intervention, subjects were additionally tested for general indexes in routine clinical practice.
The study protocol was approved by the Ethical Board of our institution. All subjects were informed and gave their signed consent before their inclusion in the study and samples were anonymized.
Lymphocytes before and after the intake of β-cryptoxanthin-enriched juice were TAP73 and ∆NP73 are expressed in relation to the reference housekeeping gene, succinate dehydrogenase complex subunit A (SDHA). The relative concentrations of TAP73, ∆NP73 and SDHA were calculated by interpolation using a standard curve of each gene plotted from a serial dilution of a cDNA prepared from the RNA of an individual expressing the specific analyzed gene. The differences in expression level of the TAP73 and ∆NP73 in a subject was calculated as the ratio, TAP73 or ∆NP73 after the intervention study:TAP73 or ∆NP73 before the intervention study. A negative sign was added when a decreased in expression was observed.
β-cryptoxanthin extraction and U-HPLC analysis
HCT116 cells were seeded on 6-well plates, allowed to attach overnight and treated as described above. Medium culture was collected and cells trypsinized, washed twice in PBS and resuspended in 1 mL of PBS. Twenty microliters of cell suspension was used to count the total cell number (ADAM Cell counter, Digital Bio). Intracellular and extracellular β-cryptoxanthin were extracted and injected onto a U-HPLC as described elsewhere (6) .
RNA extraction and reverse transcription
Total RNA was extracted using TRIsure reagent (Bioline). RNA amount was measured with a NanoDrop spectrophotometer (NanoDrop, Wilmington, DE). For the synthesis of the first-strand cDNA, 400ng of RNA was reverse-transcribed, using the Gold RNA PCR Core Kit (Applied Biosystems). Random hexamers were used as primers for cDNA synthesis.
PCR array assay
Expression profiles of genes involved in DNA damage and genes related to p53-mediated signaling pathway were studied with RT 
Viability Assays
Cells were seeded on a 96-well plate and grown overnight. Cells were pretreated and treated as described for apoptosis assays. Cell viability after treatments was tested using the MTT cell viability assay (Cayman Chemical Company).
The synergism between oxaliplatin and β-cryptoxanthin was analyzed by the combination index (CI) obtained using the Calcusyn software (Biosof) based on the 
In vivo treatment
All experiments were performed in accordance with regulations of the research welfare board of our institution. 
Immunohistochemistry analysis
Inmunohistochemistry analysis was performe by standard procedure. See
Supplementary "Materials and Methods".
Toxicity study
Body weight was monitored and clinic biochemical parameters as alaninetransaminase (ALT), aspartatetransaminase (AST), gamma-glutaminetransferase, creatinin, bilirrubin and albumin were measured.
Alkaline Single-cell Gel Electrophoresis (Comet Assay)
We followed the protocol of Singh et al. (38) (39) . See Supplementary "Materials and Methods".
Statistical analysis
The non-parametric Mann-Whitney U test was used to compare independent groups in our in vitro and in vivo experiments, whilst the Wilcoxon signed ranked test was used for paired data in the intervention study analysis. Two-tailed p values ≤ 0.05 were considered statistically significant. Statistical analysis was performed using the SPSS package version 14.0 (SPSS Inc, Chicago, IL). We used U-HPLC to measure the intracellular levels of β-cryptoxanthin in HCT116 cells before and after treatment. The net intracellular levels of β-cryptoxanthin after 24 and 48 hours of treatment were 35.444 ± 0.256 and 118.903 ± 0.362 ng/10 6 cells, respectively.
RESULTS
Cellular uptake of β-cryptoxanthin in HCT116 cells
β-cryptoxanthin regulates the levels of the TP53 family members
In order to analyze whether β-cryptoxanthin regulates the expression of genes involved in tumorigenesis, we checked the changes in two RT 2 -Profiler TM PCR Arrays (Quiagen) before and after the exposure to β-cryptoxanthin. We performed a p53 signaling pathway PCR array, which includes genes involved in processes of apoptosis, cell cycle, cell growth, proliferation, differentiation and DNA repair. In addition, as β-cryptoxanthin has antioxidant properties, a DNA Damage Signaling Pathway PCR array containing genes implicated in DNA damage response was also performed. Using a threshold value of 2-fold expression change, we found that β-cryptoxanthin affected the expression of a subset of genes in HCT116 cells, with the top 5-deregulated genes in each PCR array presented in Table S1 and Table S2 . Both PCR arrays showed upregulation of TP53 and TP73. We focused our attention on the less known TP73 gene.
β-cryptoxanthin differentially regulates the expression of TP73 isoforms in colon cancer cell lines
The treatment of HCT116 cells with β-cryptoxanthin induced an increase in 
ΔEXON2P73 mRNA levels increased 2.71-and 3.55-fold 24 and 48 hours posttreatment. (Fig. 1A) SW480-ADH cells showed upregulation of TAP73 mRNA levels of 1.8-and 16.9-fold 24 and 48 hours post-β-cryptoxanthin treatment, respectively. In contrast, a decrease of 1.81-fold in ∆NP73 expression after 48 hours was observed. ΔEXON2/3P73 mRNA levels decreased 1.21-fold after 48 hours of treatment and ΔEXON2P73 mRNA levels decreased 1.49-fold 24 hours post-treatment. (Fig. 1B) In the SW1417 cell line, no significant differences were observed in TAP73 mRNA levels after treatment. However, N-truncated terminal isoforms of TP73 were down-regulated at different times after treatment. Indeed, ∆NP73 mRNA levels decreased 5.9-fold after 48 hours, ΔEXON2/3P73 mRNA levels were reduced 4.0-fold 24 hours post-treatment and ΔEXON2P73 mRNA levels decreased 1.4-and 1.6-fold 24 and 48 hours after treatment (Fig. 1C) .
The expression of TP73 isoforms is regulated after a β-cryptoxanthin intervention study in humans
Serum levels of β-cryptoxanthin were measured by U-HPLC before and after the intervention study with a β-cryptoxanthin-enriched juice in 20 healthy volunteers. The net levels ranged from 11.6 to 75 μg/dL.
Using a random threshold value of 1.5-fold expression change, we found that the intake of the β-cryptoxanthin-enriched juice affected the expression of TP73 isoforms in 65% of subjects (Fig. 2) . Specifically, 20% of subjects presented higher levels of TAP73 in lymphocytes after β-cryptoxanthin intake, 5% presented lower levels of ∆NP73, and 25% showed both effects together. Only in 5% of the subjects did both variants decrease; 5% showed lower levels of TAP73 and 5% presented an increase in Fig. 3B) . Accordingly, incorporation of BrdU was significantly reduced in HCT116 cells treated with β-cryptoxanthin for 8 days compared to vehicle-treated cells (Fig. 3C) . The doubling time calculated for HCT116 cells treated with vehicle was 1.34 days, while the doubling time for HCT116 treated with β-cryptoxanthin was 1.47 days (p=0.002). (Fig. 3D) . Levels of ∆NP73 decreased at these exposure times although no significant differences were observed at 8 days (Fig. 3E) , but no differences in TAP73 levels were observed (data not shown). However, 10 μM β-cryptoxanthin administered alone for 6 and 8 days of treatment did not induce apoptosis (Fig. 3F) .
To assess whether ΔNP73 down-regulation by β-cryptoxanthin is involved in its anti-proliferative role, HCT116 cells were stably transfected with a pEGFP-1 plasmid encoding ΔNP73β or an empty vector, and treated for 6 and 8 days with vehicle or β-cryptoxanthin. After treatment, cell viability was tested by MTT assay. At day 6, cell viability in HCT116 mock cells treated with β-cryptoxanthin was 26% lower than that in HCT116 mock cells treated with vehicle (p=0.002). However, in HCT116 cells overexpressing ΔNP73β and treated with β-cryptoxanthin, viability was reduced by only 18% compared to vehicle treated cells (p=0.01) (Fig. S1A) overexpressing ΔNP73β and treated with β-cryptoxanthin had the same viability as cells treated with the vehicle (Fig. S1B) .
β-cryptoxanthin cooperates with oxaliplatin to induce apoptosis and reduce viability of colon cancer cells
The oxaliplatin concentration-response experiments for each cell line used in the current study are represented in Fig. S2 . HCT116 cells were pretreated for 12 hours with vehicle or 10 μM β-cryptoxanthin, and 100 µM oxaliplatin was then added for 36 hours. Oxaliplatin alone resulted in an apoptosis induction of 61.02 % compared with vehicle-treated cells. The combined treatment of oxaliplatin and β-cryptoxanthin induced an 11.5 % increase in apoptosis compared with that produced by oxaliplatin alone (p=0.05) (Fig. 4A) . Regarding viability, oxaliplatin at 100 µM decreased HCT116 cell viability to 42.4%. The combined treatment reduced cell survival to 37.8 % (p=0.02). (Fig. 4B) .
Similar results were observed with SW480-ADH and SW1417 cells. Oxaliplatin at 50 μM induced 30.3% apoptosis in SW480-ADH cells. The combination of β-cryptoxanthin and oxaliplatin significantly enhanced apoptosis by 24.6% (p=0.03). (Fig. 4A) . Viability assay in these cells showed that oxaliplatin reduced cell survival to 75.63%. The reduction in cell viability induced by the combined treatment was 15% greater than that induced by oxaliplatin alone. (p=0.03). (Fig. 4B) .
In SW1417 cells, 100 µM oxaliplatin produced 27.8% apoptosis compared to of apoptosis was 41.6%, which is 13.8% higher than that produced by the treatment with oxaliplatin alone (p=0.05) (Fig. 4A) . Similar results were obtained with the MTT assay. Oxaliplatin reduced SW1417 cell viability to 88.5 %. The combined treatment enhanced oxaliplatin activity by 21.1% (p=0.03) (Fig. 4B) .
Additionally, the combined treatment was also studied at longer times of exposure to β-cryptoxanthin. HCT116 cells were pretreated with vehicle or β-cryptoxanthin 10 μM for 6 days, and oxaliplatin 50 μM was then added for 2 days. The apoptosis assay revealed that this combined treatment with β-cryptoxanthin and oxaliplatin significantly enhanced the percentage of apoptotic cells by 11.1% (p=0.03) compared with oxaliplatin alone (Fig. 4C) . In parallel, cell viability was tested by the MTT assay and the combined treatment significantly enhanced the effect of oxaliplatin by 35.1% (p=0.02) (Fig. 4C) .
According to the Chou-Talalay method (37), the combination of both agents resulted in a synergistic effect exhibiting CI values for HCT116 cells between 0.4 and 0.7 in every combination assay (Fig. S3) . Values between 0.3-0.7 were also obtained for
SW480-ADH and SW1417 cells (data not shown).
Furthermore, colon cancer cells were treated with different concentrations of oxaliplatin. The combined treatment of oxaliplatin and β-cryptoxanthin led to a similar reduction in cell viability to that achieved by a double dose of oxaliplatin in HCT116 and SW480-ADH cells (Fig. S4) .
Impact of TP53 in response to the combined regimen
In order to evaluate the impact of TP53 in response to oxaliplatin and the combined treatment, the HCT116 TP53 null cells were used. Similar to the isogenic hours, and decreased ∆Np73 mRNA expression in 3-folds at 48 hours. As expected, HCT116 TP53 null cells were more resistant to 100 µM oxaliplatin than the wild-type cells, being the viability in the TP53 null cells of 52.3% and 42% in the wild-type (p= 0.04) (Fig. 4B) . However, no differences were observed in their response to the combined treatment, showing both cell lines a statistical significant reduction of viability compared with the oxaliplatin treatment. The percentage of viability reduction was similar in both cell lines and no statistically different ( Fig. 4B and Fig S4A) .
β-cryptoxanthin cooperates with oxaliplatin to induce apoptosis and reduce viability of colon cancer cells through ∆NP73β down-regulation
HCT116 and SW480-ADH cells were transiently transfected with a pcDNA3.1 plasmid encoding ΔNP73 or the empty vector. Subsequently, we checked the induction of apoptosis after oxaliplatin treatment or combined exposure to this chemotherapeutic agent and β-cryptoxanthin. The combined treatment enhanced the oxaliplatin effect by 11.3% (p=0.04) in HCT116 mock cells and by 8% (p=0.03) in SW480-ADH mock cells, while no differences were seen in either cell line ectopically overexpressing ΔNP73 (Fig. 5A) .
Equally, we observed that β-cryptoxanthin combined with oxaliplatin reduced HCT116 and SW480-ADH mock-cell viability by 9.43% (p=0.03) and 15.35 % (p=0.02), respectively, compared with treatment with oxaliplatin alone. No differences in cell survival between the individual and combined treatments were observed in either cell type overexpressing ΔNP73 (Fig. 5B) . Mice showed a significant decrease in tumor volume after β-cryptoxanthin administration compared with vehicle control group throughout the treatment (p<0.05).
Oxaliplatin treatment also induced marked tumor suppression (p<0.05). The combination of oxaliplatin and β-cryptoxanthin was associated with a significant decrease in tumor volume after the first (p= 0.01) and the second cycle (p= 0.02) of treatment compared with animals treated with either agent alone (Fig. 6A) .
Accordingly, tumors from mice treated with the combined regimen showed a significantly lower number of cells that were positive for the proliferative marker Ki67 than tumors from mice treated with oxaliplatin or β-cryptoxanthin alone (p=0.02 and p=0.04, respectively) (Fig. 6B) . ∆Np73 mRNA levels decreased significantly in the xenograft of mice treated with β-cryptoxanthin administrated alone (p=0.008) or in combination with oxaliplatin (p=0.055) compared with the control group (Fig. 6C) . No differences were observed in TAp73, ΔExon2p73 or ΔExon2/3p73 mRNA levels (data not shown). We evaluated TAp73 and ∆Np73 levels in kidney and liver tissues of mice kidney of mice at the end of the treatment (p=0.03). No differences were observed in TAp73 levels in kidney either in TAp73 and ∆Np73 in the liver (Fig. S5) . Finally, ∆Np73 levels were detected in 4 out of 10 mice in the group treated with vehicle, in 4 out of 10 mice treated with β-cryptoxanthin, in 7 out of 10 mice treated with oxaliplatin, and in 6 out of 10 mice treated with the combined regimen. We have observed that ∆Np73 expression was lower in the normal colonic mucosa of mice exposed to β-cryptoxanthin compared with those treated with the vehicle (p = 0.06). Similarly, mice treated with the combined regimen showed lower levels of ∆Np73 versus those treated with oxaliplatin in monotherapy (p = 0.08) (Fig. S6) . No differences in TAp73 levels were detected (data not shown).
No differences in body weight or clinical sign of toxicity were observed between vehicle treated control animals and drug treated animals (Fig. S7) . In addition, to assess whether β-cryptoxanthin has any genotoxic effect on normal cells, we performed the Comet Assay in mouse peripheral blood mononuclear cells (PBMCs). There were no significant differences in basal DNA damage between control and β-cryptoxanthin groups. As oxaliplatin can induce DNA adduct formation in white blood cells (33) , a modified version of the Comet Assay for the measurement of interstrand crosslinks was performed. We found lower formation of DNA adducts in the PBMCs of mice treated with the combination of β-cryptoxanthin and oxaliplatin compared to mice treated with oxaliplatin alone (TM= 4.98±0.14 vs 4.33±1.65; p=0.04; TI=28.71±1.78 vs 25.09±1.65; p=0.055, respectively) (Fig. S8) . In the present study we observed that β-cryptoxanthin down-regulates the expression of the oncogenic ∆NP73, which could be associated with the cancer protective effect previously described for this carotenoid. In parallel, we observed inhibition of cell growth by β-cryptoxanthin in vitro and in our animal model. This finding was associated with a decrease in the number of cells in the S-phase. Since no apoptosis was detected in our experiments we conclude that the growth inhibitory effect of this compound is largely due to anti-proliferative activity. Similar data have been reported in lung and stomach cells, suggesting broad anti-proliferative properties for β-cryptoxanthin in both normal and tumor cells (29, 30) . Interestingly, the overexpression of ∆NP73 abrogates the effect of β-cryptoxanthin, which supports the hypothesis that the negative regulation of this specific variant could be one of the mechanisms underlying the effects of this carotenoid. Nishino and coworkers previously suggested mRNA levels of ΔNp73 in xenograft tumors after the two cycles of treatment. *p=0.05, **p<0.01. Mean ± standard deviation of 7 mice per group is represented.
